TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05317858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier Disruption - Oncology
Description: BBB opening via Exablate Type 2 system with microbubble resonators on the day of pembrolizumab infusion to treat brain metastases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab infusion
Study: NCT05740748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: tezepelumab 210 mg sc q4wks for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sc q4wks for 20 weeks
Study: NCT04320888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/CT, and/or CT/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI, PET/MRI, and/or CT/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET, PET/CT, and/or PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo scintigraphy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT05979727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RE02
Description: Low, medium or high dose of RE02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RE02
Description: Low, medium or high dose of RE02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RE02
Description: Low, medium or high dose of RE02

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Manitol
Description: Placebo Comparator
Study: NCT04947735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacle lenses
Description: Single vision, impact resistant spectacle lenses
Study: NCT04981860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenova
Description: One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenova
Description: One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenova
Description: One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenova
Description: One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
Study: NCT05845931

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
Study: NCT04870957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainGuide
Description: A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.
Study: NCT04392258

Intervention type: DIAGNOSTIC_TEST
Intervention: TSH determination
Description: Determination of serum concentration of thyrotropin (TSH)

Intervention type: DIAGNOSTIC_TEST
Intervention: FT4 determination
Description: Determination of serum free thyroxine (FT4) concentration

Intervention type: DIAGNOSTIC_TEST
Intervention: FT3 determination
Description: Determination of serum free triiodothyronine (FT3) concentration

Intervention type: DIAGNOSTIC_TEST
Intervention: SPINA-GT
Description: Calculation of thyroid's secretory capacity (SPINA-GT)

Intervention type: DIAGNOSTIC_TEST
Intervention: SPINA-GD
Description: Calculation of total deiodinase activity (SPINA-GD)
Study: NCT05149144

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
Description: Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio signal dataset creation and validation; machine learning analysis, empirical evaluations
Description: The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
Study: NCT05983523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP07
Description: PEP07 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
Study: NCT04763447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attempt to withdrawal OMA treatment
Description: Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of OMA treatment
Description: Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care.
Study: NCT06365320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single basketball training
Description: Single basketball training session with fixed intensity and duration
Study: NCT04870957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT and exercise
Description: Participants will take part in 10 physical therapy visits over the course of 8 weeks. Participants will meet with the physical therapist twice a week for a 1-hour session for weeks 1 and 2 and then weekly for the remaining 6 weeks. The physical therapist will tailor a program to the participant's needs according to recommended PT practice guidelines that will include in-person treatment, home exercise prescription, and encouragement of progressive, low-intensity, submaximal fitness and endurance activities, such as walking.~Participants will be given a home program of exercises to be done daily and asked to engage in daily walking with a set goal based on the individual's capacity and current fitness level. Walking was selected as the aerobic exercise of focus for this treatment because it is recommended for patients with all levels of pain severity, is highly feasible to complete, and has shown effects on outcomes such as pain and disability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self -administered acupressure
Description: A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions.
Study: NCT05332691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transapical beating-heart septal myectomy
Description: We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
Study: NCT04870957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self -administered acupressure
Description: A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions.
Study: NCT05926635

Intervention type: DEVICE
Intervention: ATLAS 2030
Description: sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
Study: NCT06195865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP-flap
Description: Breast reconstruction with a deep inferior epigastric perforator flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP-flap
Description: Breast reconstruction with a deep inferior epigastric perforator flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Breast reconstruction with an implant-based technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Breast reconstruction with an implant-based technique
Study: NCT05269563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Pars Plana Vitrectomy for Macular Hole Closure
Study: NCT00620581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
Study: NCT05877430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJRB-101
Description: In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks
Study: NCT06180798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cold snare endoscopic mucosal resection (C-EMR)
Description: All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used .~submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.~Bleeding will be assessed for 2 mins to decide upon requirement of immediate hemostatic methods in the form of clipping or electrocoagulation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (H-EMR)
Description: All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.submucosal injection of saline mixed with methylene blue will be used.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.~After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
Study: NCT05753709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand sewn end-to-end anastomosis
Description: Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand sewn side-to-side anastomosis
Description: Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled side-to-side anastomosis
Description: Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
Study: NCT06404775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mastalgia-oil, tamoxifen placebo
Description: external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mastalgia-oil placebo, tamoxifen
Description: oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
Study: NCT06504264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phonemic segmentation
Description: during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phonemic segmentation
Description: during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.
Study: NCT06512545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second allogeneic stem cell transplantation
Description: 1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)
Study: NCT06587750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Multisensory Rehabilitation
Description: CMR targets somatosensory and multisensory and cognitive functions through sensory discrimination exercises.
Study: NCT04113382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLENPIQ
Description: CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL.
Study: NCT05520866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrehabPal
Description: Web based application
Study: NCT04113382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLENPIQ
Description: CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIRALAX
Description: MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIRALAX
Description: MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
Study: NCT06674018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indole-3-propionic acid
Description: A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indole-3-propionic acid
Description: A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
Study: NCT06504264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phonemic segmentation
Description: during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.